Last reviewed: July 2, 2026 Last updated: July 2, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Compounding pharmacies may face restrictions similar to what happened with compounded semaglutide when Ozempic faced shortage declarations and subsequent regulatory scrutiny
Read More Get updated every time I publish new content and receive exclusive offers
The concept of "best time to apply" becomes less about pharmacokinetic optimization and more about practical convenience and skin site rotation
Jayne Hornung, chief clinical officer at Managed Markets Insight and Technology, suggests initial pricing of oral GLP-1s for weight loss could be reminiscent of the early days of anti-CGRP medications for migraines when the first oral CGRP came to market in 2019, the pricing still remained high
a , Comparison of compound 2 (grey) docked to the GLP-1R crystal structure, after 500 ns molecular dynamics simulation (compound 2 in cyan), and molecular dynamics simulation of PF-06372222-bound GLP-1R (PF-06372222 in pink)
